Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 06 Dec 2022 16:45 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination With KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive Head and Neck Cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 23 Nov 2022 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report 3Q 2022 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 16 Nov 2022 16:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to announce financial results for the third quarter 2022 and host webcast presentation on November 23, 2022 | 20103010 Biotechnology | Non-regulatory press releases |
| 07 Nov 2022 16:30 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics presents additional efficacy analysis in Phase 2 study of VB10.16 in combination with atezolizumab in advanced cervical cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 07 Nov 2022 08:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to present at two upcoming investor conferences in November | 20103010 Biotechnology | Non-regulatory press releases |
| 28 Oct 2022 08:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to Present a Poster on Interim Results from the Pre-planned Interim Analysis from the C-02 trial with VB10.16 in advanced cervical patients at the European Society of Gynaecological Oncology’s 23rd Annual Meeting (ESGO 2022) | 20103010 Biotechnology | Non-regulatory press releases |
| 26 Oct 2022 16:30 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Presentation of Positive Immunogenicity Results from Phase 1/2a Study of VB10.NEO, an Individualized Therapeutic Cancer Vaccine, at the Neoantigen-Based Therapies Summit | 20103010 Biotechnology | Non-regulatory press releases |
| 24 Oct 2022 17:58 CEST |
NYKODE THERAPEUTICS ASA | Mandatory notification of intra group transfer of shares by primary insider’s related party | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 27 Sep 2022 06:45 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Positive Results from the Phase 1/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate | 20103010 Biotechnology | Inside information |
| 09 Sep 2022 17:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to present at H.C. Wainwright 24th Annual Global Investment Conference | 20103010 Biotechnology | Non-regulatory press releases |
| 08 Sep 2022 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to be included in the Oslo Børs Benchmark Index (OSEBX) and the Oslo Børs Mutual Fund Index (OSEFX) | 20103010 Biotechnology | Non-regulatory press releases |
| 26 Aug 2022 16:44 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA - Mandatory notification for close associate of primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 24 Aug 2022 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report 2Q 2022 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 22 Aug 2022 06:45 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to announce financial results for the first half of 2022 and host webcast presentation on August 24, 2022 | 20103010 Biotechnology | Non-regulatory press releases |
| 04 Jul 2022 20:50 CEST |
NYKODE THERAPEUTICS ASA | Grant of Share Options | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 15 Jun 2022 15:54 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - approval and publication of prospectus and admission to trading on the Oslo Stock Exchange’s main list | 20103010 Biotechnology | Prospectus / admission document |
| 13 Jun 2022 10:32 CEST |
NYKODE THERAPEUTICS ASA | Oslo Børs – Vedtak om opptak til handel – Nykode Therapeutics ASA | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 13 Jun 2022 10:32 CEST |
NYKODE THERAPEUTICS ASA | Oslo Børs - Decision on admission to trading – Nykode Therapeutics ASA | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 13 Jun 2022 08:35 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics appoints Klaus Edvardsen as Chief Development Officer | 20103010 Biotechnology | Non-regulatory press releases |
| 08 Jun 2022 15:19 CEST |
NYKODE THERAPEUTICS AS | Søknad om overføring av aksjer tatt opp til handel fra Euronext Growth til Oslo Børs | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 08 Jun 2022 15:19 CEST |
NYKODE THERAPEUTICS AS | Application for transfer of shares admitted to trading on Euronext Growth to Oslo Børs | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 02 Jun 2022 15:45 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics ASA - Conversion to public limited liability company registered | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 01 Jun 2022 08:00 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics to Present at Jefferies Healthcare Conference | 20103010 Biotechnology | Non-regulatory press releases |
| 18 May 2022 16:00 CEST |
NYKODE THERAPEUTICS ASA | Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 16 May 2022 20:50 CEST |
NYKODE THERAPEUTICS AS | Grant of share options | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 16 May 2022 08:00 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics - Quarterly report Q1 2022 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 12 May 2022 10:50 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics AS - Minutes of Annual General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 11 May 2022 19:12 CEST |
NYKODE THERAPEUTICS AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 09 May 2022 06:45 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics announces positive interim results from its Phase 2 trial with VB10.16 in combination with immune checkpoint inhibitor atezolizumab in advanced cervical cancer | 20103010 Biotechnology | Inside information |
| 06 May 2022 12:45 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics – Invitation to Capital Markets Day in Oslo on May 12, 2022 | 20103010 Biotechnology | Non-regulatory press releases |
| 05 May 2022 08:00 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics AS - Notice of Annual General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 19 Apr 2022 08:30 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics to host Capital Markets Day | 20103010 Biotechnology | Non-regulatory press releases |
| 19 Apr 2022 08:00 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics to present at Kempen Life Sciences Conference | 20103010 Biotechnology | Non-regulatory press releases |
| 08 Apr 2022 19:00 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics announces presentation of preclinical data from its second generation Vaccibody vaccine technology at 2022 American Association for Cancer Research (AACR) Annual Meeting | 20103010 Biotechnology | Non-regulatory press releases |
| 08 Apr 2022 15:35 CEST |
NYKODE THERAPEUTICS AS | Registration of new share capital | 20103010 Biotechnology | Total number of voting rights and capital |
| 01 Apr 2022 07:00 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics - full year 2021 financial results and corporate presentation | 20103010 Biotechnology | Non-regulatory press releases |
| 31 Mar 2022 23:30 CEST |
NYKODE THERAPEUTICS AS | Mandatory notification of exercise of warrants and sale of shares to primary insider’s related party | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 31 Mar 2022 19:00 CEST |
NYKODE THERAPEUTICS AS | Nykode Therapeutics reports full year 2021 financial results | 20103010 Biotechnology | Annual financial and audit Reports |
| 28 Mar 2022 08:00 CEST |
NYKODE THERAPEUTICS AS | Nykode to announce full year 2021 financial results on March 31, 2022 and host webcast presentation on April 1, 2022 | 20103010 Biotechnology | Non-regulatory press releases |
| 08 Mar 2022 22:30 CET |
NYKODE THERAPEUTICS AS | Nykode Therapeutics to Present at 2022 American Association for Cancer Research (AACR) Annual Meeting | 20103010 Biotechnology | Non-regulatory press releases |
| 01 Mar 2022 15:11 CET |
NYKODE THERAPEUTICS AS | Share capital increase from exercise of warrants | 20103010 Biotechnology | Total number of voting rights and capital |
| 22 Feb 2022 12:30 CET |
NYKODE THERAPEUTICS AS | Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 15 Feb 2022 15:04 CET |
NYKODE THERAPEUTICS AS | Mandatory notification of exercise of warrants | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 14 Feb 2022 06:45 CET |
NYKODE THERAPEUTICS AS | Nykode Therapeutics to Present at SVB Leerink 2022 Global Healthcare Conference | 20103010 Biotechnology | Non-regulatory press releases |
| 11 Feb 2022 06:45 CET |
NYKODE THERAPEUTICS AS | Nykode Therapeutics announces completion of patient enrollment in its Phase 2 trial of VB10.16 in combination with atezolizumab for the treatment of advanced cervical cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 30 Dec 2021 17:31 CET |
NYKODE THERAPEUTICS AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 28 Dec 2021 06:45 CET |
NYKODE THERAPEUTICS AS | Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate | 20103010 Biotechnology | Non-regulatory press releases |